1. United States
2. Nev.
3. Letter

-- Dear Senator/Representative, I am a your state constituent writing to respectfully ask for your support of the ISLET Act as it comes before committee review. This legislation addresses a federal regulatory issue that limits Americans with type 1 diabetes from accessing a therapy developed in the United States. Donor pancreatic islets are human cellular tissue, like organs and other transplantable tissue, but they are currently regulated as a manufactured drug product. This classification creates barriers that make the therapy largely inaccessible through standard U.S. transplant programs. While islet transplantation is provided as standard care in several other developed countries, in the U.S. it is primarily limited to research settings. The ISLET Act does not create a new therapy or weaken safety oversight; it simply places donor islets within the appropriate organ and tissue transplant framework, maintaining regulation and patient protections while removing unnecessary obstacles to care. Type 1 diabetes is a lifelong autoimmune disease requiring constant monitoring and insulin therapy. Even with modern treatment, patients face daily medical management and the risk of severe complications. Islet transplantation has been shown to reduce dangerous hypoglycemic events and improve quality of life for carefully selected patients. The ISLET Act is a practical regulatory correction rather than an expansion of government. It aligns policy with biological reality, supports American medical innovation, and helps ensure patients in the U.S. can access this therapy safely. I respectfully ask that you support the ISLET Act and help move this legislation forward. Thank you for your time, service, and for considering this request on behalf of the nearly two million Americans living with type 1 diabetes.